2007 Immune Response Molecular Biology Therapies 
Dark Matter Blog
JULY 16, 2021
The only subject in school that held my interest was biology. As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. I wanted to use molecular biology to create drugs. I had a first-hand role in raising money from Wall Street by being part of an IPO roadshow as Synta went public in 2007.
Drug Discovery World
MAY 12, 2023
The toxicities associated with cancer therapies are significant. These side effects not only contribute to a lower functional status and quality of life but can also lead to delays and discontinuation of therapy that decrease treatment effectiveness and increase the morbidity and mortality of the disease 3. The possibilities are vast.
Expert insights. Personalized for you.
52 
Let's personalize your content